Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,558 | $1,955 | $2,112 | $2,756 |
| - Cash | $32 | $18 | $39 | $16 |
| + Debt | $101 | $99 | $119 | $103 |
| Enterprise Value | $1,627 | $2,036 | $2,192 | $2,843 |
| Revenue | $75 | $77 | $78 | $86 |
| % Growth | -2.4% | -1.6% | -8.9% | – |
| Gross Profit | $57 | $64 | $65 | $73 |
| % Margin | 76.1% | 83.3% | 83.5% | 84.8% |
| EBITDA | $34 | $44 | $46 | $40 |
| % Margin | 45% | 56.7% | 59% | 46.8% |
| Net Income | $20 | $27 | $29 | $28 |
| % Margin | 26.7% | 34.5% | 37.2% | 32.9% |
| EPS Diluted | 4.5 | 5.96 | 6.53 | 6.33 |
| % Growth | -24.5% | -8.7% | 3.2% | – |
| Operating Cash Flow | $46 | $41 | $25 | $12 |
| Capital Expenditures | -$14 | -$16 | -$15 | -$17 |
| Free Cash Flow | $32 | $25 | $10 | -$4 |